Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study
Year: 2020
Type: article
Source: Blood
Authors: Jason Gotlib, Deepti H. Radia, Tracy I. George, William A Robinson, Albert T. Quiery, Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott F. Winton, Hans-Peter Horny, Meera Tugnait, Oleg Schmidt-Kittler, Erica K. Evans, Hui-Min Lin, Brenton G. Mar, Michael W. Deininger, Daniel J. DeAngelo
Institutions: Stanford Medicine, Stanford Cancer Institute, Stanford University, Guy's and St Thomas' NHS Foundation Trust, University of Utah, ARUP Laboratories (United States), University of Michigan, Beatson West of Scotland Cancer Centre, The University of Texas MD Anderson Cancer Center, Abramson Cancer Center, University of Pennsylvania, Emory University, Winship Cancer Institute, Pathologisches Institut, Ludwig-Maximilians-Universität München, Blueprint Medicines (United States), Huntsman Cancer Institute, Dana-Farber Cancer Institute
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3095612443